South Korea advanced a major overhaul to drug review and pricing, aiming to rebalance incentives toward innovation while tightening controls for generics. The reforms target how the country evaluates medicines for reimbursement and sets pricing trajectories, representing a notable shift for a market with outsized global generic volume. The direction mirrors broader Asia-Pacific pressure to reward novel therapies and limit the fiscal impact of lower-cost competitors. For biotech developers, changes to the reimbursement and review rubric can materially affect launch strategy, pricing expectations, and the timing of market access. The announcement also increases uncertainty for sponsors of generics and follow-on products, as pricing controls may evolve in parallel with review standards.